Low power blue LED exposure increases effects of doxorubicin on MDA-MB-231 breast cancer cells

Photodiagnosis Photodyn Ther. 2018 Dec:24:250-255. doi: 10.1016/j.pdpdt.2018.07.016. Epub 2018 Jul 29.

Abstract

Patients with triple negative breast cancer can develop side effects as a result of chemotherapy. Photodynamic therapy may reduce these side effects if the chemotherapy agent could also act as a photosensitizer. Thus, the aim of this work was to evaluate cytotoxicity and reactive oxygen species production induced by doxorubicin and low power blue LED in breast cancer cultures. Cell viability and reactive oxygen species (ROS) in MDA-MB-231 cultures were evaluated in response to different doxorubicin concentrations and blue LED fluences. Compared with control, cell cultures only incubated with doxorubicin at 25 nM showed 23% of cell viability reduction while its combination with blue LED at 640 J/cm2 reduced 40% of cell viability after 24 h. After 48 h, reduction of cell viability raises to 40% in cell cultures only incubated with doxorubicin and 55% when combined with blue LED. Evaluation 30 min after treatment showed that cells incubated with doxorubicin and exposed to blue LED generated 22% more ROS than controls. Those results show that incubation with doxorubicin combined with exposure to low power blue LED is more cytotoxic and more effective to increase ROS levels in MDA-MB-231 cultures than incubation with doxorubicin alone.

Keywords: Cancer; Doxorubicin; LED; Photodynamic therapy.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / pharmacology*
  • Female
  • Humans
  • Photochemotherapy / methods*
  • Photosensitizing Agents / pharmacology*
  • Reactive Oxygen Species / metabolism
  • Triple Negative Breast Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Photosensitizing Agents
  • Reactive Oxygen Species
  • Doxorubicin